Abstract
Certain characteristics of tumor cells make it possible to develop rational strategies for targeting tumors without harming normal cells. These include the presence of cell surface molecules that characterize the current state of the tumor (e.g. CD30 on Hodgkin lymphoma cells) and the genetic and epigenetic changes that activate oncogenes and inactivate tumor suppressor genes (e.g. the inactivation of tumor suppressor gene DAPK2 in Hodgkin lymphoma cells, which blocks apoptosis). We have developed a novel tumor-targeting fusion protein by combining a selective ligand (CD30L) with a constitutively active version of DAPK2 (DAPK2-CD30L), thus increasing tumor specificity and reducing systemic toxicity. We showed that this immunokinase fusion protein induces apoptosis specifically in CD30+/DAPK2 – tumor cells in vitro and significantly prolonged overall survival in a disseminated Hodgkin lymphoma xenograft SCID mouse model. Therapeutic strategies based on the cell-specific restoration of a defective, tumor-suppressing kinase demonstrate the feasibility of targeted therapy using recombinant immunokinases
Keywords: Immunotherapy, targeted cancer therapy, serine/threonine protein kinases, CaM kinases, apoptosis, autophagy, therapeutic fusion protein, immunotoxins
Current Pharmaceutical Design
Title: Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
Volume: 15 Issue: 23
Author(s): Mehmet Kemal Tur, Inga Neef, Gernot Jager, Andreas Teubner, Michael Stocker, Georg Melmer and Stefan Barth
Affiliation:
Keywords: Immunotherapy, targeted cancer therapy, serine/threonine protein kinases, CaM kinases, apoptosis, autophagy, therapeutic fusion protein, immunotoxins
Abstract: Certain characteristics of tumor cells make it possible to develop rational strategies for targeting tumors without harming normal cells. These include the presence of cell surface molecules that characterize the current state of the tumor (e.g. CD30 on Hodgkin lymphoma cells) and the genetic and epigenetic changes that activate oncogenes and inactivate tumor suppressor genes (e.g. the inactivation of tumor suppressor gene DAPK2 in Hodgkin lymphoma cells, which blocks apoptosis). We have developed a novel tumor-targeting fusion protein by combining a selective ligand (CD30L) with a constitutively active version of DAPK2 (DAPK2-CD30L), thus increasing tumor specificity and reducing systemic toxicity. We showed that this immunokinase fusion protein induces apoptosis specifically in CD30+/DAPK2 – tumor cells in vitro and significantly prolonged overall survival in a disseminated Hodgkin lymphoma xenograft SCID mouse model. Therapeutic strategies based on the cell-specific restoration of a defective, tumor-suppressing kinase demonstrate the feasibility of targeted therapy using recombinant immunokinases
Export Options
About this article
Cite this article as:
Tur Kemal Mehmet, Neef Inga, Jager Gernot, Teubner Andreas, Stocker Michael, Melmer Georg and Barth Stefan, Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923877
DOI https://dx.doi.org/10.2174/138161209788923877 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioinformatics Approach for Data Capturing: The Case of Breast Cancer
Current Cancer Therapy Reviews Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes
Anti-Cancer Agents in Medicinal Chemistry Approaches for Gene Discovery and Defining Novel Protein Interactions and Networks
Current Genomics Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design Raloxifene: Cardiovascular Considerations
Mini-Reviews in Medicinal Chemistry Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry The Neuroendocrine System as a Model to Evaluate Experimental Gene Therapy
Current Gene Therapy MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion
Current Medicinal Chemistry Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Current Genomics Cervical Cancer and Human Papillomaviruses: Inactivation of Retinoblastoma and Other Tumor Suppressor Pathways
Current Molecular Medicine The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents